News & events

Press Releases

On the 28th March 2022, OncoArendi changed its name to Molecure

Molecure submits application to the European Medicines Agency (EMA) to initiate a phase II clinical trial in the European Union and Norway to investigate OATD-01 for the treatment of pulmonary sarcoidosis

9 September 2023

The U.S. Food and Drug Administration Gives the Green Light to Molecure’s Flagship Program – Phase II Clinical Testing of OATD-01 is Ready for Launch

22 July 2023

Molecure completes successful Secondary Public Offering of approximately USD 12 million with proceeds to be used to fund and build a first in class, sustainable pipeline of breakthrough therapies

19 July 2023

Molecure has signed an agreement to conduct a Phase II clinical trial for its lead molecule OATD-01, taking another important step in the development of this program.

3 July 2023

Molecure Files an Investigational New Drug (IND) application for lead clinical candidate OATD-01 with U.S. FDA ahead of a planned Phase 2 pulmonary sarcoidosis study

22 June 2023

Molecure Announces Full Year Financial 2022 Results – A Year of Significant Progress

30 March 2023

Events & Presentations

ESMO – 8-12 September 2017 Madrid

1 September 2017

ERS – 9-13 September 2017 Milan

1 September 2017

BIO USA – San Diego 19-22 June 2017

1 June 2017

ATS – Washington 19-24 May 2017

1 May 2017